SYNTRIX BIOSYSTEMS, INC.

Basic Information

215 CLAY ST NW, STE B-5
AUBURN, WA, 98001-4213

Company Profile

n/a

Additional Details

Field Value
DUNS: 114845659
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Phase II clinical evaluation of Omnitram in neuropathic pain

    Amount: $224,997.00

    DESCRIPTION provided by applicant Neuropathic pain is caused by damage to the peripheral nerves as occurs in diabetic neuropathy Neuropathic pain is difficult to treat and many patients have pai ...

    SBIR Phase I 2015 Department of Health and Human Services National Institutes of Health
  2. Efficacy and resistance mechanisms of LD-aminopterin in psoriasis

    Amount: $225,000.00

    DESCRIPTION (provided by applicant): Psoriasis is a chronic, genetically influenced, remitting and relapsing scaly and inflammatory skin disorder that affects 1-3% of the world's population, resu ...

    SBIR Phase I 2014 Department of Health and Human Services
  3. Overcoming Tramadol Resistance In CYP2D6 Poor Metabolizers

    Amount: $1,793,961.00

    DESCRIPTION (provided by applicant): Tramadol is a widely prescribed analgesic, with over 25 million prescriptions and 565 million in retail sales in 2009, making it among the best selling generic d ...

    SBIR Phase II 2012 Department of Health and Human Services
  4. Optimization of CXCR1/2 antagonist SX-576 for the treatment of BPD and COPD

    Amount: $3,846,324.00

    DESCRIPTION (provided by applicant): SX-576 is a small molecule CXCR1/2 antagonist that potently blocks the migration of neutrophils to sites of injury and/or inflammation. SX-576 is being developed a ...

    SBIR Phase II 2011 Department of Health and Human Services
  5. Transition-State Analogue Inhibitors of Dihydrofolate Synthetase for MDR/XDR TB

    Amount: $557,508.00

    DESCRIPTION (provided by applicant): Mycobacterium tuberculosis (Mtb) is a notorious pathogen whose increasing resistance to antibiotics and heightened lethality in combination with AIDS makes it a ma ...

    SBIR Phase I 2011 Department of Health and Human Services
  6. 99mTc-DTB-Antifol-Pteroyls (RadioDAPs): Theranostics for Rheumatoid Arthritis

    Amount: $590,144.00

    DESCRIPTION (provided by applicant): Rheumatoid arthritis (RA) occurs in 2,100,000 people in the United States, and is associated with progressive joint destruction, functional disability and decrease ...

    SBIR Phase I 2010 Department of Health and Human Services
  7. Overcoming Tramadol Resistance In CYP2D6 Poor Metabolizers

    Amount: $649,545.00

    DESCRIPTION (provided by applicant): Tramadol is a widely prescribed analgesic, with 18,526,000 prescriptions and 281,559,000 in retail sales in 2007, making it the 31st best selling generic drug. On ...

    SBIR Phase I 2010 Department of Health and Human Services
  8. PhotoMorph3 and PhotoPS3- Novel Light-Activated Antisense Agents

    Amount: $698,900.00

    DESCRIPTION (provided by applicant): The spatiotemporal modulation of gene expression using targeted light to activate antisense molecules promises to have an important impact in transparent model or ...

    SBIR Phase I 2009 Department of Health and Human Services
  9. The Treatment of Methotrexate Resistant Rheumatoid Arthritis With Aminopterin

    Amount: $518,627.00

    DESCRIPTION (provided by applicant): The long term goal of this project is to develop aminopterin (AMT), an antifolate medication, as an improved treatment for patients with rheumatoid arthritis (RA) ...

    SBIR Phase I 2009 Department of Health and Human Services
  10. Aminopterin for the Treatment of Severe Recalcitrant Atopic Dermatitis

    Amount: $587,148.00

    DESCRIPTION (provided by applicant): Atopic dermatitis (AD) is an itchy, inflammatory skin disease. It is one of the most common causes of human and canine disability. The incidence of human atopic de ...

    SBIR Phase I 2008 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government